• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • TNF Blocking Agent
    3 Drugs classified under this drug class


    All the Drug Class Drugs

    Enbrel
    Pfizer
    RX
    partial basket chart
    Enbrel

    TNF Blocking Agent. Etanercept 25, 50 mg.
    (pwdr. for inj.): 25 mg.
    PRE-FILL. SYR. (soln for inj.): 1 x 25 mg;
    1 x 50 mg.
    PRE-FILL. PEN (soln for inj.): 1 x 50 mg.
    Dosage must be ajust. individ.
    RA: Tmt. of active RA in adult. when the
    response to DMARDs include.
    methotrexate (unless contraindic. ) has
    been inadeq. Can be used in comb. with
    methotrexate in pts. who do not respond
    adeq. to methotrexate alone. Reduc.
    signs&sympt. and inhibit. the progress. of
    structur. damage in pts. with moder. –
    sev. act. RA.
    Alone or in comb. with methotrexate, has
    been shown to reduce the rate of
    progress. of joint damage as measure. by
    X-ray and to improve. physic. funct.
    Polyarticul. juven. idiopathic arthrit.:
    Tmt. of active polyarticul. juven.
    idiopathic arthrit. in child. & adolesc. ≥2
    yrs. who have had an inadeq. respon. to,
    or who have proved intoler. of,
    methotrexate. The drug has not been
    studi. in child. < 2 yrs.
    Psor. arthrit.: Tmt. of act. & progress. psor.
    arthrit. in adults when the response to
    prev. DMARDs ther. has been inadeq.
    The has been shown to improve. physic.
    func. in pts. with psoriat. arthrit., and to
    reduce the rate of progress. of peripher.
    joint damage as measured by X ray in pts.
    with polyarticul. symmetric. subtypes of
    the dis.
    Ankylos. spondyl.: Tmt. of adult. with sev.
    act. ankylos. spondyl. who have had an
    inadeq. response to convent. ther.
    Plaque psorias.: Tmt. of adults pts. (18 yrs.
    or older) with moderate to severe plaque
    psor. who are candidates for system. ther.
    or photother.
    Ped. plaque psor. Tmt. of chron. sev.
    plaque psor. in child. &adolesc. from the
    age of 6 yrs. who are inadeq. control. by,
    or are intoler. to, other system. ther. or
    photother.
    Juven. idiopat. arthrit. tmt. of polyarthrit.
    (rheumat. factor posit. or neg.) and
    extended oligoarthritis in child. &
    adolesc. ≥2 yrs who have had an inadeq. response to, or who have proved intoler.
    of, methotrexate.
    Tmt. of psor. arthrit. in adolesc. ≥12 yrs.
    who have had an inadeq. response to, or
    who have proved intol. of, methotrexate.
    Tmt. of enthesitis-related arthrit. in
    adolesc. ≥ 12 yrs. who have had an
    inadeq. respon. to, or who have proved
    intoler. of, convent. ther.
    Axial spondyloarthritis Ankylos.
    spondylitis: Tmt. of adults with sev. active
    ankylosing spondylitis who have had an
    inadeq. response to convent. ther.
    Non-radiograph. axial spondyloarthritis:
    Tmt. of adult. with sev. non-radiograph.
    axial spondyloarthritis with object. signs
    of inflamm. as indic. by elev. CRP and MRI
    evidence, who have had an inadeq.
    response to NSAIDs.
    C/I: Hypersens., sepsis or risk of sepsis,
    Pts. with active infec. , includ. chron. or
    localised infec.

    Humira 20, 40, 80 mg
    AbbVie
    RX
    partial basket chart
    Humira 20, 40, 80 mg

    TNF Blocking Agent. Adalimumab 20 mg / 0.2 ml, 40 mg / 0.4 ml, 80 mg / 0.8 ml.
    PRE-FILLED SYRINGE: 2 (20 mg/0.2 mL, 40mg/0.4ml, 80 mg/0.8 mL).
    PRE-FILLED PEN: 2. (40mg /0.4ml, 80 mg/0.8 mL).
    VIAL (with adaptor): 2. S.C. Dosage must be adjust. individ. accord. to pt. med. cond.
    RA: In comb. with methotrexate: The tmt. of moder.- sev., active RA in adult pts.
    when the response to dis.-modif. anti-rheumatic drugs include. methotrexate has been inadequate.
    The tmt. of severe, active and progres. RA in adults not prev. treated with methotrexate. Can be given as monother. in case of intoler. to methotrexate or when continued tmt. with methotrexate is inapprop.
    This drug has been shown to reduce the rate of progres. of joint damage as measured by X-ray and to improve physic. funct., when given in comb. with methotrexate.
    Juvenile idiopat. arthritis Polyarticular juvenile idiopat. arthritis: In comb. with methotrexate- tmt. of active polyarticular juvenile idiopat. arthritis, in pts. from the age of 2 yrs. who have had an inadequate response to one or more DMARDs. Adalimumab can be given as monother. in case of intoler. to methotrexate or when continued tmt. with methotrexate is inapprop. (for the efficacy in monother.). Adalimumab has not been studied in pts. aged less than 2 yrs.
    Axial spondyloarthritis, Ankylosing spondylitis (AS): Tmt. of adults with sev. act.  ankylos. spondylitis who have had an inadequate response to convent. ther.
    Axial spondyloarthritis without radiographic evidence of AS: Tmt. of adults with severe axial spondyloarthritis without radiograp. evidence of AS, but with object. signs of inflame. by radiolog. and/or lab.tests includ. MRI and serum CRP levels, who have had an inadequate response to, or are intoler. to, non-steroidal anti-inflam. drugs.
    Psoriatic arthritis: Tmt. of active and progres. psoriat. arthritis in adult. when the response to previous dis.-modif. anti-rheum. drug ther. has been inadequate. Adalimumab has been shown to reduce the rate of progres. of periph. joint damage as measured by X-ray in pts. with polyarticular symmetr. subtypes of the dis. and to improve physic. funct.
    Psoriasis: Tmt. of moder.- sev. chron. plaque psoriasis in adult pts. who are candidates for systemic ther.
    Ped. plaque psoriasis: Tmt. of sev. chron. plaque psoriasis in child. and adolesc. from 4 yrs. of age who have had an inadequate response to or are inappropr. candidates for topical ther. and phototherapies. Hidradenitis suppurativa (HS): Tmt. of active moder.- sev. HS (acne inversa) in adult, adolesc. from 12 yrs. of age with an inadequate response to convent. syst. HS ther.
    Crohn’s dis.: Indic. for reduc. signs and sympt. and induc. and maintain. clin. remiss. in adult pts. with moder. - sev. active Crohn’s dis. who have had an inadequate response to conven. ther. The drug is indic. for reduc. signs and sympt. and induc. clin. remiss. in these pts. if they have also lost response to or are intoler. to infliximab.
    Ped.Crohn's dis.: Tmt. of moder. – sev. active Crohn's dis. in ped. pts. (from 6 yrs. of age) who have had an inadequate response to convent. ther. include. prim. nutrition ther. and corticosteroid, and/or an immunomodulator, or who are intoler. or have contraindic. for such ther.
    Ulcer. colit.: Tmt. of moder.- sev. active ulcer. colit. in adult pts. who have had an inadequate response to conven. ther.  include. corticoster. and 6-mercaptopurine or azathioprine, or who are intoler. to or have med. contraind. for such therap.
    Enthesitis-related arthritis: Tmt. of active enthesitis-related arthritis in pts., 6 yrs. of age and older, who have had an inadequate response to, or who are intoler. of conven.  ther.
    Uveitis: Tmt. of non-infec. intermediate, posterior and panuveitis in adult pts. who have had an inadequate response to corticosteroid., in pts. in need of corticosteroid sparing, or in whom corticosteroid tmt. is inappropriate.
    Intestinal Behcet's dis.: Tmt. of intestinal Behcet’s dis. in pts. who have had an inadequate response to convent. ther.
    C/I: Hypersens. Active tuberc., other severe  infec. such as sepsis, and opportun. infec. Moder. - severe HF(NYHA class III/IV).

    Simponi
    Janssen
    RX
    not in the basket chart
    Simponi

    TNF Blocking Agent. Golimumab 50 mg/0.5 ml.
    PREFILLED PEN: 1 x 0.5 ml.
    PREFILLED SYRINGE: S.C. 1 x monthly,
    same date.
    Rheumatoid arthrit: In comb. with
    methotrexate. Psoriatic arthrit: Alone/in
    combinat. with methotrexate.Ankylosing
    spondyl.
    Ulcerative ColitisSimponi is indicated for
    treatment of moderately to severely active
    ulcerative colitis in adult patients who
    have had an inadequate response to
    conventional therapy including
    corticosteroids and 6-mercaptopurine
    (6-MP) or azathioprine (AZA), or who are
    intolerant to or have medical
    contraindications for such therapies.
    C/I: Hypersens., activte tuberculosis/
    other severe infect., mod/severe heart
    fail.

    CLOSE